EGFR and non-small cell lung carcinoma: A large subset of NSCLC patients exhibit enhanced signaling of the epidermal growth factor receptor (EGFR) and/or the hepatocyte growth factor receptor (cMet), with EGFR inhibition being an effective clinical treatment option for NSCLC [2,3].